206 related articles for article (PubMed ID: 36555547)
1. The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands.
Maurer S; Zhong X; Prada BD; Mascarenhas J; de Andrade LF
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555547
[TBL] [Abstract][Full Text] [Related]
2. Role of Polymorphisms of NKG2D Receptor and Its Ligands in Acute Myeloid Leukemia and Human Stem Cell Transplantation.
Machuldova A; Holubova M; Caputo VS; Cedikova M; Jindra P; Houdova L; Pitule P
Front Immunol; 2021; 12():651751. PubMed ID: 33868289
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
4. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
5. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
[TBL] [Abstract][Full Text] [Related]
6. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
8. Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia.
Wu Z; Zhang H; Wu M; Peng G; He Y; Wan N; Zeng Y
Biomed Pharmacother; 2021 May; 137():111299. PubMed ID: 33508619
[TBL] [Abstract][Full Text] [Related]
9. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
11. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
[TBL] [Abstract][Full Text] [Related]
12.
Liu M; Du M; Yu J; Qian Z; Gao Y; Pan W; Zhao X; Wang M; Li H; Zheng J; Huang Q; Wang LM; Xiao H
Oncoimmunology; 2022; 11(1):2016158. PubMed ID: 35003895
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
14. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
15. [Expression of NKG2D and NKG2A with their ligands MHC-I A/B and HLA-E in acute leukemia patients and its significance].
Ge SJ; Duan LN; Luo Y; Suo TL; Lu CR; Tang J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):312-6. PubMed ID: 21518478
[TBL] [Abstract][Full Text] [Related]
16. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.
Hussein BA; Kristenson L; Pesce S; Wöhr A; Tian Y; Hallner A; Brune M; Hellstrand K; Tang KW; Bernson E; Thorén FB
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648262
[TBL] [Abstract][Full Text] [Related]
17. c-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis.
Nanbakhsh A; Pochon C; Mallavialle A; Amsellem S; Bourhis JH; Chouaib S
Blood; 2014 Jun; 123(23):3585-95. PubMed ID: 24677544
[TBL] [Abstract][Full Text] [Related]
18. Ataxia-telangiectasia mutated kinase-mediated upregulation of NKG2D ligands on leukemia cells by resveratrol results in enhanced natural killer cell susceptibility.
Luis Espinoza J; Takami A; Trung LQ; Nakao S
Cancer Sci; 2013 Jun; 104(6):657-62. PubMed ID: 23445485
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of NKG2D ligands by AML cells to increase sensitivity to NK cells: the tumour might strike back. Comment on "differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis" by Rohner et al. [Leuk Res 2007;31:1393-402].
Zimmer J; Michel T; Andrès E; Hentges F
Leuk Res; 2008 Apr; 32(4):676-7. PubMed ID: 17920678
[No Abstract] [Full Text] [Related]
20. Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells.
Holubova M; Leba M; Gmucova H; Caputo VS; Jindra P; Lysak D
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
